alexa
Reach Us +44-176-4910199
Trial Of Lamivudine In Hepatitis-B Surface Antigen Carriers With Persistence Hepatitis-B Core IgM Antibody | 7742
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Trial of lamivudine in hepatitis-B surface antigen carriers with persistence hepatitis-B core IgM antibody

World Congress on Gastroenterology & Urology

Husham YMA Bayazed

ScientificTracks Abstracts: J Gastrointest Digest Sys

DOI: 10.4172/2161-069X.S1.02

Abstract
Background & Aims: The persistence of hepatitis B core IgM antibody in hepatitis B surface antigen carrier is a risk factor with hidden danger and forecast existence of liver damage. A trial of lamivudine in such subset of carriers was carried on for the first time in this study. Patients & Methods: A total of 62 hepatitis B surface antigen with hepatitis e antibody individuals (age range, 25-45 years) with persistence hepatitis B core IgM antibody were randomized to receive either 100 mg lamivudine (32/62) or placebo (30/62) daily for 6 months. Results: Among lamivudine group, hepatitis B core IgM antibody seroclearance achievement rate was 81.3% and HBsAg seroconversion rate was 9.4 % compared to 6.3% and 3.3% in placebo group respectively. A number of adverse clinical events were observed, but were of mild nature and tolerable by the participants who completed the study. Conclusion: Trial of lamivudine in this subset of hepatitis B surface antigen carriers proven to be safe and efficacious. More studies are needed prior to recommending the drug for routine use on selected HBV carriers.
Biography
Prof Dr Husham YMA Bayazed, Dean of Technical & Health Institute-Zakho, Ministry of Higher Education and Scientific Research, Kurdistan Regional Government-Iraq. Consultant of Microbiology & Immunology and have published till now 22 papers in reputed journals. On the other hand, being a membership in many national and International Committees such membership of Iraqi Viral Hepatitis Committee, Fellowship of ISC, Infection and Cancer, membership of World Stroke Organization and Immunology Advisory Board Member of EUROMDnet, Brussels, Belgium.
Top